Ir para o conteúdo principal

United StatesÚltimas notícias

Grafa

European Commission approves Dupixent for children aged 2–11 with chronic spontaneous urticaria

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) announced on April 13, 2026, that the European Commission, has expanded the marketing authorization for Dupixent (dupilumab) to include children aged 2 to 11 years with moderate-to-severe chronic spontaneous urticaria (CSU).

Leia mais
Bloomberg

Iran War Drives Oil Shock

As the conflict in Iran continues, there's growing concern about oil volatility and whether this is the beginning of a true supply disruption. Market Intelligence Founder & Director Amrita Sen joins Christina Ruffini and Tim Stenovec on Bloomberg This Weekend to discuss.

Leia mais